A Detailed Analysis of Clinical Features and Outcomes of Patients with Pyogenic Spondylodiscitis Presenting without Axial Back Pain

Study design: Retrospective analysis of a single institution prospective, longitudinal database of spinal pyogenic infections. Diagnosis of pyogenic spondylodiscitis (PS) can be challenging. Although presenting symptoms are often non-specific, acute non-remitting axial back pain is the most striking feature. Nevertheless, several authors have reported on the uncommon occurrence of patients with PS without axial back pain. The aim of this study was to characterize presenting symptoms, causative agents, comorbidities, and treatment outcomes of patients presenting with painless pyogenic spondylodiscitis. A total of 214 patients diagnosed with PS were reviewed; patients were divided into two groups: patients presenting with no axial back pain (no pain group, n = 16), and patients presenting with axial back pain (control group, n = 198). Analyzed data comprised general demographics, presenting symptoms, comorbidities, spinal infection location, and amount of spinal involvement. While average age (62.4 vs. 65.0) and sex distribution was similar between the two groups, a significant diagnostic delay was noted in the control group (53 vs. 17 days, p < 0.001). Patients in the no pain group were more likely IV drug abusers or have had liver failure/cirrhosis. Anatomic distribution (i.e., cervical vs thoracolumbar) of the infection did not differ between the two groups, but a higher number of post-surgical infections was noted in the no pain group (37.5 vs. 15.6%, p = 0.026). E. coli and Pseudomonas spp. were more commonly seen in no pain group patients, and mortality was also higher in this group (12.5 vs. 6.0%, p = 0.004).

[1]  L. Nasto,et al.  Uncorrect diagnosis of tubercolar spondylodiscitis in aggressive and bone destructive metastasis of melanoma: A case report and literature review , 2020, Orthopedic reviews.

[2]  M. Bassetti,et al.  Hot Topics on Vertebral Osteomyelitis from the International Society of Antimicrobial Chemotherapy. , 2019, International journal of antimicrobial agents.

[3]  G. Maccauro,et al.  Multidisciplinary management of pyogenic spondylodiscitis: epidemiological and clinical features, prognostic factors and long-term outcomes in 207 patients , 2018, European Spine Journal.

[4]  R. Cauda,et al.  New classification for the treatment of pyogenic spondylodiscitis: validation study on a population of 250 patients with a follow-up of 2 years , 2017, European Spine Journal.

[5]  F. Oner,et al.  Outcome of conservative and surgical treatment of pyogenic spondylodiscitis: a systematic literature review , 2016, European Spine Journal.

[6]  E. K. Nickerson,et al.  Vertebral osteomyelitis in adults: an update. , 2016, British medical bulletin.

[7]  A. Widmer,et al.  Executive Summary: 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  A. Widmer,et al.  2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  M. Dupon,et al.  Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial , 2015, The Lancet.

[10]  A. Lassen,et al.  Increasing incidence of pyogenic spondylodiscitis: a 14-year population-based study. , 2014, The Journal of infection.

[11]  C. Fisher,et al.  Primary Pyogenic Infection of the Spine in Intravenous Drug Users: A Prospective Observational Study , 2012, Spine.

[12]  E. Trecarichi,et al.  Epidemiological and clinical features of pyogenic spondylodiscitis. , 2012, European review for medical and pharmacological sciences.

[13]  Alpesh A. Patel,et al.  Vertebral Osteomyelitis , 2010 .

[14]  G. d’Ettorre,et al.  A Seven-Year Prospective Study on Spondylodiscitis: Epidemiological and Microbiological Features , 2010, Infection.

[15]  E. Mylona,et al.  Pyogenic vertebral osteomyelitis: a systematic review of clinical characteristics. , 2009, Seminars in arthritis and rheumatism.

[16]  J. Desenclos,et al.  Epidemiology of vertebral osteomyelitis (VO) in France: analysis of hospital-discharge data 2002–2003 , 2007, Epidemiology and Infection.

[17]  A. Feydy,et al.  Comparative study of postoperative and spontaneous pyogenic spondylodiscitis. , 2005, Seminars in arthritis and rheumatism.

[18]  A. Freemont,et al.  Nerve growth factor expression and innervation of the painful intervertebral disc , 2002, The Journal of pathology.

[19]  Kirk A Easley,et al.  Vertebral osteomyelitis: long-term outcome for 253 patients from 7 Cleveland-area hospitals. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.